Research programme: RapaTag therapies - Rapafusyn Pharmaceuticals
Alternative Names: RapTag programsLatest Information Update: 13 May 2025
At a glance
- Originator Rapafusyn Pharmaceuticals
- Class Cyclic peptides; Macrocyclic compounds
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 23 Oct 2024 Early research in Unspecified in USA (unspecified route) prior to October 2024 (Rapafusyn Pharmaceuticals pipeline, October 2024)